Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Predictive Oncology Inc. POAI

Predictive Oncology Inc. (NASDAQ: POAI) Enters into Definitive Agreements for Direct Offering Totaling Estimated $3 Million

Posted on February 10, 2021 by MissionIR

Definitive agreements with institutional, accredited investors call for issuance and sale of more than 3.5 million shares of common stock POAI currently focused on applying AI to develop personalized medical treatments, novel lab media and improved vaccines One of POAI’s … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Stands to Benefit from Explosive Growth of Precision Medicine

Posted on February 8, 2021 by MissionIR

Precision medicine in oncology allows for clinicians to develop personalized cancer treatment plans using individual characteristics of each patient Doctors use insights drawn from laboratory-grown cancer cells, patients’ DNA to individualize cancer treatment Predictive Oncology has been forerunner in its … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Launches Project Focused on Ovarian Cancer Utilizing Proprietary PeDAL(TM) Platform

Posted on February 8, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Regained Compliance with Nasdaq’s Minimum Bid Price Requirement

Posted on February 3, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (NASDAQ). The letter informed Predictive Oncology … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Ranked as Buy in Litchfield Hills Recent Analyst Report

Posted on February 2, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been rated as a “Buy” in the first analyst coverage report released by equity research firm Litchfield Hills Research LLC. … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology (NASDAQ: POAI) Subsidiary Working to Individualize, Improve Ovarian Cancer Treatment Options

Posted on January 28, 2021 by MissionIR

Ovarian cancer is a leading cause of death, causes more death than any other female reproductive system cancer POAI’s Helomics dedicated to improving clinical decision making for ovarian cancer patients Helomics has pioneered testing of drugs on patients’ own tumors … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $4.1 Million

Posted on January 27, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970 shares of POAI’s common stock, … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering

Posted on January 22, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announced Definitive Agreements for $2.2 Million Registered Direct Offering

Posted on January 19, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements for the issuance and sale of more than 2 million shares of its common stock. The … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Subsidiary Sells Media to Top Research Medical Centers

Posted on January 14, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in New York City and Boston. … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment